After a year where the COVID-19 pandemic has impacted the world economy and healthcare, the priorities have been set to a well-rounded vaccination program and understanding the “new normality”. By January 2021, more than 100 million cases had been reported, with Europe and North America accountable for ~60%. During this period, Mexico started facing new records in hospitalizations and deaths, leading the healthcare system to maximum capacity and a set of new restrictions by the Government.
As cases increased during the end of 2020 and beginning of 2021, different vaccines such as the ones from: Pfizer-BioNTech and Moderna were approved for application in USA, the EEC and other continents. For the scientific community, the development of this vaccines has been a milestone, as some of them such as the one from Pfizer is based on an mRNA (Message ARN) mechanism. For Mexico, the approval of different vaccines has rolled-out the vaccination program with plans of completing it by 2022. Additionally, it has represented an opportunity for the massive production and distribution phases. Moving forward, it is important for organizations to continue with cautious strategies and prepare for growth once the pandemic is over.
(PDF Article Only Available in Spanish)